We evaluated coenzyme Q 10 (CoQ) levels in patients studied under suspicion of mitochondrial DNA depletion syndromes (MDS) (n=39). 
Introduction
Mitochondrial DNA depletion syndromes (MDS) are a heterogeneous group of disorders characterized by low number of mitochondrial DNA (mtDNA) copies in different tissues (Spinazzola, 2011) . These syndromes are frequently associated with severe infant and childhood mitochondrial respiratory chain (MRC) deficiencies and patients may present with different phenotypes. Myopathic (OMIM: 609560), encephalomyopathic (OMIM: 612073 and 612075) and hepatocerebral (OMIM 251880) are common forms, although a wide range of clinical presentations are being profiled (Nogueira et al., 2011; Rotig and Poulton, 2009; Suomalainen and Isohanni, 2010) .
MDS have been related to impaired mtDNA replication (mutations in POLG1 and
C10orf2/PEO1 genes), to altered mitochondrial metabolism of deoxynucleotide pools (mutations in TK2, DGUOK, MPV17, RRM2B, SUCLA2, SUCLG1 and TYMP genes) (Nogueira et al., 2011; Rotig and Poulton, 2009; Suomalainen and Isohanni, 2010) .
However, in a high percentage of the cases the aetiology of the disease remains to be elucidated (Alberio et al., 2007) .
Coenzyme Q 10 (CoQ) is a mobile molecule that acts as an electron carrier in the MRC transferring electrons from complex I and complex II to complex III (Ernster and Dallner, 1995) . It is also a cofactor for several mitochondrial dehydrogenases, including dihydroorotate dehydrogenase (EC 1.3.3.1), an enzyme involved in pyrimidine biosynthesis. A link between CoQ deficiency and impaired pyrimidine biosynthesis has previously been demonstrated (Lopez-Martín et al., 2007) , although only anecdotic reports have studied CoQ status in MDS patients (Montero et al., 2009 (Quinzii et al., 2010;  A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT Sacconi et al., 2010; Salviati et al., 2012) , mutations in the ADCK3 gene have been associated with cerebellar ataxic form of CoQ deficiency (Langier-Tourenne et al., 2008 ) and a mutation in the COQ6 gene that causes nephrotic syndrome with sensorineural deafness (Heeringa et al., 2011) . Interestingly, several studies have reported the presence of a secondary CoQ deficiency in diseases such as ataxia with oculomotor apraxia (Quinzii et al., 2005) and glutaric aciduria type II (Gempel et al., 2007) . CoQ deficiency has also been frequently detected in mitochondrial disorders Miles et al., 2008; Sacconi et al., 2010 , Quinzii et al., 2011 , Emmanuele et al., 2012 . In our global experience, CoQ deficiency is present in a similar percentage of patients with mitochondrial disorder to that reported in the study by Montero et al., 2005 . Furthermore, secondary CoQ deficiency may be very difficult to differentiate from that of primary deficiency, since in most cases the molecular basis of the disease remains elusive (Emmanuele et al, 2012) .
The aim of the present study was to evaluate muscle and liver CoQ levels in a cohort of patients with a clinical phenotype suggestive of MDS.
Methods

Patients:
During the last 3 years, we have recruited 39 patients (age range: 1 month -24 years; average 2.6 years) with the following inclusion criteria: clinical phenotype suggestive of MDS; no CoQ supplementation therapy at the time of the biopsy; biochemical, histopathological and/or genetic evidence of a mitochondrial disease according to previously established criteria for diagnosis of mitochondrial disease (Bernier et al., 2002) . 12 patients were from Coimbra, 4 patients from London and 23 patients from
Barcelona. The patients were classified in 2 groups.
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Laboratory studies:
MRC and citrate synthase (CS) enzyme activities were determined by spectrophotometric enzyme assays in muscle biopsies as previously reported (Rustin et al., 1994; Grazina, 2012) . We assessed MRC enzyme activities corrected for citrate synthase activity, and MRC deficiencies were considered as described by Grazina et al., 2012 and Bernier et al, 2002. Muscle and liver CoQ levels were determined by reverse-phase high pressure liquid chromatography (HPLC, Waters, MA, USA) with electrochemical detection (ED;
Coulochem II, ESA, MA, USA) (Montero et al., 2008) . Briefly, CoQ was separated on a 
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been previously reported (Montero et al., 2008) . The muscle CoQ status of patients from the UK was determined by HPLC with UV detection at 275 nm (Jasco UV 975 detector, Jasco, UK) (Duncan et al., 2005) . Genetic analyses of candidate genes associated with MDS (POLG1, DGOUK, MPV17, RRM2B, TK2, C10orf2, SUCLG1 and SUCLA2) were performed or are under investigation in all patients, belonging to group 1. In group 2, molecular analyses in mitochondrial or nuclear DNA were performed according to the clinical and biochemical phenotype of the patients. Briefly, the mtDNA ATPase gene was sequenced in 2 patients, the mtDNA cytochome b was sequenced in 2 patients, and 32 different mtDNA point mutations were also assessed in 3 patients. Mitochondrial DNA
rearrangements were investigated in muscle biopsies from 3 patients from the UK patients, 9 from Portugal and 5 patients from Spain, all with negative results.
Ethical issues:
Patients and their parents signed informed consent for genetic studies. The remaining 9 patients with MDS are still under investigation for an underlying genetic cause (no mutations have been found in 6 patients selected for POLG analysis).
In 1 of the 25 patients with no MDS (Group 2), a novel mtDNA mutation in tRNA has A C C E P T E D M A N U S C R I P T and the % mtDNA depletion (r= -0.597; p<0.001). CS activity was also found to be negatively correlated with the % mtDNA depletion (r= -0.561; p<0.0001).
In the liver samples, no differences were observed in CoQ levels between groups 1 and 2, and only 1 patient with MDS was found to have a liver CoQ status (132 nmol/g) below the reference interval (table 2).
Discussion
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To our knowledge, no previous studies have determined the CoQ status in patients with MDS, besides a single case study (Montero et al., 2009) into the mitochondria. Furthermore, the possibility arises that some as yet unknown genetic factor may confer susceptibility to develop secondary a CoQ deficiency since not all patients with MDS were found to have a deficit in CoQ10 status. In addition, the degree of the diminution in CoQ status was found to be variable in our series of patients with MRC disorders as has also been reported in other studies (Miles et al., 2008; Montero et al., 2005; Sacconi et al., 2010) . In view of the involvement of CoQ in pyrimidine biosynthesis, where the reduced form of CoQ, ubiquinol plays as an essential cofactor role for dyhydroorotate dehydrogenase, (Lopez-Martín et al., 2007) , the possibility arises that a deficit in CoQ status may contribute to MDS due to a perturbation of pyrimidine synthesis. Among the patients examined in the present study,
a good candidate would be case 11, who presented with a severe neonatal encephalopathy associated with MDS and a profound CoQ deficiency. However, in this case CoQ-related genes were sequenced but no pathogenic mutations were detected (data not shown). Moreover, to our knowledge no evidence of mtDNA depletion has been reported in patients with primary genetic CoQ deficiency, although the close relationship between CoQ status and pyrimidine biosynthesis deserves further investigation. Unfortunately, in the preponderance of patients with MDS the definite molecular diagnosis remains elusive. An investigation into the molecular basis of MDS in these patients will be essential to understand the association between CoQ deficiency and mtDNA depletion.
Classically, primary CoQ deficient patients present with a reduction in the activities of both MRC complexes I + III and II + III, since the activities of these enzymes is dependent on endogenous CoQ (Ogasahara et al., 1989) . A proportion of our MDS CoQ deficient patients presented with a generalized MRC defect as expected, but not with a specific reduction in the activities of the CoQ-dependent MRC complexes.
These phenomena may be explained by the fact that the global loss of MRC enzyme complex activities may mask the specific reduction of I + III or II + III activities associated with CoQ deficiency (Sacconi et al., 2010) . Interestingly, decreased MRC complex IV activity appears to be associated with CoQ deficiency as indicated by the Chi-Square test. However, this finding may be explained by a primary loss of MRC complex IV activity in MDS (COX negative fibers are usually observed in the myopathic form of MDS; Nogueira et al., 2011; Spinazzola, 2011) .
Interestingly, a significant correlation was determined between mtDNA depletion and CoQ status. This correlation reinforces the hypothesis that a CoQ deficiency may be involved in the pathophysiology of MDS. Furthermore, CoQ levels were also associated
with CS activity, a well known marker of mitochondrial number and volume (Montero et al., 2008) . This association enforces the possibility that as has been reported for CS activity (Navarro-Sastre et al., 2012) , that the CoQ deficiency associated with MDS may be a secondary consequence of a reduction in mitochondrial number and volume.
CoQ deficiency is a treatable condition (Trevisson et al., 2011) . However, the use CoQ therapy in the treatment of MRC disorders has not generally been found to be efficacious. In the Sacconi (2010) (Quinzii and Hirano, 2011) . However, further work will be required before this can be confirmed or refuted.
Conclusions
In conclusion, in this study we have found evidence of an association between CoQ deficiency and MDS. In the absence of a definite molecular diagnosis in most cases, we cannot at present determine whether a CoQ deficiency is a primary or a secondary factor in the disease pathophysiology of MDS. However, the results of the present study indicate that a CoQ deficiency may be a secondary consequence of mitochondrial DNA depletion. We acknowledge the technical support of Sonia Moliner and Nuria Buján is a PhD student of the University of Girona. Case 13, patient with pathologic % mtDNA depletion in brain, was excluded of this table. A C C E P T E D M A N U S C R I P T 
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